University of Oxford spin-out OMass Therapeutics has moved into a new purpose-designed research and development facility at ARC Oxford.
The biotech firm has signed a deal with Brookfield’s life sciences arm, Advanced Research Clusters, the operator of the business park,
Thank you for reading EG
Want to read more? Enjoy a story a week for FREE for one month.
